Jin‐Ji Yang

8.8k citations

146 papers · 4.9k indexed · 2 hit papers · h-index 36

Impact in

Oncology top 0.5%
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
Pulmonary and Respiratory Medicine top 0.5%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Brain Metastases and Treatment

Papers in

Oncology 102
- Lung Cancer Research Studies 46
- Colorectal Cancer Treatments and Studies 32
- Cancer Immunotherapy and Biomarkers 20
Pulmonary and Respiratory Medicine 121
- Lung Cancer Treatments and Mutations 117
- Lung Cancer Diagnosis and Treatment 31
- Brain Metastases and Treatment 10

Co-authors: Yi‐Long Wu Xu‐Chao Zhang Qing Zhou Hong‐Hong Yan Wen‐Zhao Zhong Hai‐Yan Tu Jian Su Xue‐Ning Yang
Journals: Journal of Thoracic Oncology (22 papers)Journal of Clinical Oncology (17 papers)Lung Cancer (13 papers)Clinical Lung Cancer (7 papers)Oncotarget (6 papers)
Partner nations: China United States United Kingdom

In The Last Decade

Jin‐Ji Yang

138 papers receiving 4.9k citations

Hit Papers

align trajectories log scale

Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: A real-world study 2023 · 110 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2023 Cell Reports Medicine
2016 Clinical Cancer Research

Peers

Countries citing papers authored by Jin‐Ji Yang

Since Specialization

Citations

This map shows the geographic impact of Jin‐Ji Yang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jin‐Ji Yang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jin‐Ji Yang more than expected).

Fields of papers citing papers by Jin‐Ji Yang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jin‐Ji Yang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jin‐Ji Yang. The network helps show where Jin‐Ji Yang may publish in the future.

Co-authors

The 25 scholars most cited alongside Jin‐Ji Yang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jin‐Ji Yang Line = papers co-authored together Jin‐Ji Yang links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	APOC1 inhibit NKTCL doxorubicin sensitivity by promoting mitophagy IUBMB Life ·Sa Xiao, Jing Kuang, Jin‐Ji Yang, Haili Wang, Yingying Sun, Haipeng Zhang, Zhongyu Zhang, Mengyuan Shi, Kun Qi, Miao Jiang, Yanyan Zhang, Qingjiang Chen, Xudong Zhang	2025	0
2	WS02.13 PD-L1 Expression Guidance on Sintilimab versus Pembrolizumab in Untreated Advanced NSCLC (CTONG1901) Journal of Thoracic Oncology ·S.-Y.M. Liu, Jie Deng, Hong‐Hong Yan, Ming‐Yu Yang, Chong‐Rui Xu, Mingying Zheng, Boon Chye Gan, X.-C. Zhang, Hanjun Tu, Jin‐Ji Yang, H.-J. Chen, B.-C. Wang, Yun Li, Qing Zhou, Yi‐Long Wu	2023	1
3	PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trial Science Bulletin ·Si‐Yang Maggie Liu, Jie Huang, Jia‐Yi Deng, Chong‐Rui Xu, Hong‐Hong Yan, Mingyi Yang, Yang-Si Li, (unknown), E‐E Ke, Ming-Ying Zheng, Zhen Wang, Jiaxin Lin, Bin Gan, Xu‐Chao Zhang, Hua‐Jun Chen, Bin-Chao Wang, Hai‐Yan Tu, Jin‐Ji Yang, Wen‐Zhao Zhong, (unknown), (unknown), Qing Zhou, Yi‐Long Wu	2023	18
4	Genomic and Transcriptomic Analysis of Neuroendocrine Transformation in ALK-Rearranged Lung Adenocarcinoma After Treatments With Sequential ALK Inhibitors: A Brief Report JTO Clinical and Research Reports ·Jie Huang, Shi-Ling Zhang, Chaozheng Zhou, Weiye Huang, Peng Luo, Hua‐Jun Chen, Jin‐Ji Yang	2022	9
5	Clinical outcomes of EGFR+/METamp+ vs. EGFR+/METamp‐ untreated patients with advanced non‐small cell lung cancer Thoracic Cancer ·Kai‐Cheng Peng, Junwei Su, Zhi Xie, Hanmin Wang, Mei‐Mei Fang, Wenfeng Li, Yuqing Chen, Xuhui Guan, Jian Su, Hong‐Hong Yan, Xu‐Chao Zhang, Hai‐Yan Tu, Qing Zhou, Hua‐Jun Chen, Yi‐Long Wu, Jin‐Ji Yang	2022	11
6	Clinical outcomes of non–small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments European Journal of Cancer ·Mei-Mei Zheng, Hai‐Yan Tu, Jin‐Ji Yang, Xu‐Chao Zhang, Qing Zhou, Chong‐Rui Xu, Ben‐Yuan Jiang, Xue‐Ning Yang, Xiaorong Yang, Jia‐Yi Deng, Mingyi Yang, Bing-Fei Xu, Xiu‐Mei Chen, Yang-Si Li, Yi‐Long Wu	2021	19
7	High SHP2 expression determines the efficacy of PD‐1/PD‐L1 inhibitors in advanced KRAS mutant non‐small cell lung cancer Thoracic Cancer ·Hui‐Bo Feng, Yu Chen, Zhi Xie, Jie Jiang, Yumin Zhong, Wei‐Bang Guo, Wenqing Yan, Zhiyi Lv, Danxia Lu, Hong‐Ling Liang, Fangping Xu, Jin‐Ji Yang, Xue‐Ning Yang, Qing Zhou, Dong‐Kun Zhang, Zhou Zhang, Shaokun Chuai, Henghui Zhang, Yi‐Long Wu, Xu‐Chao Zhang	2021	9
8	Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study Cancer Cell ·Qing Zhou, Chong‐Rui Xu, Ying Cheng, Yunpeng Liu, Gongyan Chen, Jiuwei Cui, Nong Yang, Yong Song, Xiaoling Li, Shun Lü, Jianying Zhou, Zhiyong Ma, Shiying Yu, Cheng Huang, Yongqian Shu, Zhen Wang, Jin‐Ji Yang, Hai‐Yan Tu, Wen‐Zhao Zhong, Yi‐Long Wu	2021	144
9	Mutational landscape and characteristics of ERBB2 in non‐small cell lung cancer Thoracic Cancer ·Xue‐Wu Wei, Xin Gao, Xu‐Chao Zhang, Jin‐Ji Yang, Zhihong Chen, Yi‐Long Wu, Qing Zhou	2020	35
10	Intratumoral heterogeneity of EGFR-activating mutations in advanced NSCLC patients at the single-cell level BMC Cancer ·Longhua Guo, Zhihong Chen, Chong‐Rui Xu, Xuchao Zhang, Hong‐Hong Yan, Jian Su, Jin‐Ji Yang, Zhi Xie, Wei‐Bang Guo, Feng Li, Yi‐Long Wu, Qing Zhou	2019	16
11	Heterogeneous responses and resistant mechanisms to crizotinib in ALK‐positive advanced non‐small cell lung cancer Thoracic Cancer ·Jin‐Hyoung Kang, Hua‐Jun Chen, Xu‐Chao Zhang, Jian Su, Qing Zhou, Hai‐Yan Tu, Zhen Wang, Binchao Wang, Wen‐Zhao Zhong, Xue‐Ning Yang, Zhihong Chen, Yan Ding, Xue Wu, Mei Wang, Jiangang Fu, Zhenfan Yang, Xian Zhang, Yang Shao, Yi‐Long Wu, Jin‐Ji Yang	2018	17
12	P2.03b-043 Peripheral Blood CD45RA+ CCR7+ Naive T Cells Were Correlated with Prognosis in Non-Small Cell Lung Cancer Patients Journal of Thoracic Oncology ·Shu‐Mei Huang, Si-Pei Wu, Ri-Qiang Liao, Zhong‐Yi Dong, Hai‐Yan Tu, Zhi Xie, Jian Su, Jin‐Ji Yang, Xu‐Chao Zhang, Yi‐Long Wu	2017	1
13	Characterization of PD-L1 expression in Chinese non-small cell lung cancer patients with PTEN expression as a means for tissue quality screening Cancer Immunology Immunotherapy ·Xu‐Chao Zhang, Xu Cao, Chun Sun, Zhi Xie, Jianjun Guo, Jin‐Ji Yang, Xue‐Ning Yang, Hangjun Dai, Su-chun Li, Xinran Xu, Yunxia Zuo, Meng Chen, Hartmut Koeppen, Jing He, Astrid Kiermaier, David S. Shames, Gang Cheng, Yi‐Long Wu	2017	4
14	Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma Clinical Cancer Research ·Zhong‐Yi Dong, Wen‐Zhao Zhong, Xu‐Chao Zhang, Jian Su, Zhi Xie, Si‐Yang Maggie Liu, Hai‐Yan Tu, Hua‐Jun Chen, Yue‐Li Sun, Qing Zhou, Jin‐Ji Yang, Xue‐Ning Yang, Jiaxin Lin, Hong‐Hong Yan, Hao-Ran Zhai, Li‐Xu Yan, Ri-Qiang Liao, Si-Pei Wu, Yi‐Long Wu Hit paper breakdown →	2016	741
15	Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC Lung Cancer ·Yi‐Long Wu, Nagahiro Saijo, Sumitra Thongprasert, James Chih‐Hsin Yang, Baohui Han, Benjamin Margono, B. Chewaskulyong, Patrapim Sunpaweravong, Yuichiro Ohe, Yukito Ichinose, Jin‐Ji Yang, Tony Mok, Helen Young, Vincent Haddad, Yuri Rukazenkov, Masahiro Fukuoka	2016	40
16	Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations Journal of Thoracic Oncology ·Yang-Si Li, Ben‐Yuan Jiang, Jin‐Ji Yang, Hai‐Yan Tu, Qing Zhou, Wei‐Bang Guo, Hong‐Hong Yan, Yi‐Long Wu	2016	211
17	[Burden of disease attributed to high total cholesterol in 2013 in China]. PubMed ·Jin‐Ji Yang, Z Q Wang, Yan Zhao, Y C Li, Peng Yin, S.W. Liu, Jin-Zong You, M G Zhou	2016	1
18	[Consensus on dignosis for ALK positive non-small cell lung cancer in China, the 2013 version]. PubMed ·Xu‐Chao Zhang, Shun Lu, Li Zhang, Changli Wang, Ying Cheng, Gan‐di Li, Tony Mok, Cheng Zhi Huang, Xiaoqing Liu, Jie Wang, Mengzhao Wang, Yiping Zhang, Jianying Zhou, Xiaoyan Zhou, Dongmei Lin, Jin‐Ji Yang, Hui Li, Haiquan Chen, Wen‐Zhao Zhong, Yi‐Long Wu	2013	22
19	BCL11A overexpression predicts survival and relapse in non-small cell lung cancer and is modulated by microRNA-30a and gene amplification Molecular Cancer ·Ben‐Yuan Jiang, Xuchao Zhang, Jian Su, Wei Meng, Xue‐Ning Yang, Jin‐Ji Yang, Qing Zhou, Zhiyong Chen, Zhihong Chen, Zhi Xie, Shiliang Chen, Yi‐Long Wu	2013	46
20	A Clinical Model to Estimate the Pretest Probability of Lung Cancer, Based on 1198 Pedigrees in China Journal of Thoracic Oncology ·Huan Lin, Wen‐Zhao Zhong, Xue‐Ning Yang, Xu‐Chao Zhang, Jin‐Ji Yang, Qing Zhou, Hong‐Hong Yan, Ri-Qiang Liao, Qiang Nie, Song Dong, Yi‐Long Wu	2012	14

About Jin‐Ji Yang

Jin‐Ji Yang is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Hepatology and Pathology and Forensic Medicine, having authored 146 papers that have together received 4.9k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (117 papers), Lung Cancer Research Studies (46 papers), Colorectal Cancer Treatments and Studies (32 papers), Lung Cancer Diagnosis and Treatment (31 papers), Cancer Genomics and Diagnostics (30 papers), Cancer Immunotherapy and Biomarkers (20 papers), RNA modifications and cancer (11 papers) and Brain Metastases and Treatment (10 papers). The work is most often cited by research in Oncology (3.5k citations), Pulmonary and Respiratory Medicine (3.9k citations), Cancer Research (1.1k citations), Molecular Biology (1.2k citations) and Pathology and Forensic Medicine (295 citations). Jin‐Ji Yang has collaborated with scholars based in China, United States and United Kingdom. Frequent co-authors include Yi‐Long Wu, Xu‐Chao Zhang, Qing Zhou, Hong‐Hong Yan, Wen‐Zhao Zhong, Hai‐Yan Tu, Jian Su, Xue‐Ning Yang, Hua‐Jun Chen and Zhi Xie. Their work appears in journals such as Journal of Thoracic Oncology, Journal of Clinical Oncology, Lung Cancer, Clinical Lung Cancer and Oncotarget.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact